Indications |
Oral Influenza A Adult: 100 mg daily for 5 days. Elderly: >65 yr: Daily dose of <100 mg or 100 mg given at intervals >1 day.
Oral Prophylaxis of influenza A Adult: 100 mg daily for up to 6 wk; when used with influenza vaccination: only up to 3 wk after vaccination. Child: 10-15 yr: 100 mg daily.
Oral Herpes zoster in immunocompromised patients Adult: 100 mg bid for 14 days, continued for another 14 days if pain persists.
Oral Parkinson's disease Adult: Initially, 100 mg/day, increased to 100 mg bid after a wk or more. Max dose: 400 mg daily. Elderly: >65 yr: Lowest effective dose. Special Populations: Reduce dose in patients with renal impairment. |
||||||||||||||||||||||||
Contraindications |
Hypersensitivity. Pregnancy and lactation. Epilepsy or other seizure disorders, severe renal impairment and gastric ulceration. | ||||||||||||||||||||||||
Warnings / Precautions |
Patients with CV or liver disease, impaired renal function, recurrent eczema. Elderly. Withdrawal of the drug should be gradual. | ||||||||||||||||||||||||
Adverse Reactions |
Seizures, psychosis, hallucinations, confusion, ataxia, heart failure, depression, orthostatic hypotension, blood dyscrasias, urinary retention, irritability, GI disturbances, anorexia, livedo reticularis, ankle oedema. Potentially Fatal: Congestive heart failure, convulsions. |
||||||||||||||||||||||||
Overdose Reactions |
Cardiac arrest may occur. | ||||||||||||||||||||||||
Drug Interactions |
Enhances the adverse effects of antimuscarinics and levodopa. CNS stimulants, drugs that raise urinary pH. See Below for More amantadine Drug Interactions |
||||||||||||||||||||||||
Mechanism of Actions |
Amantadine is a weak dopamine agonist possessing antimuscarinic properties. It alters dopamine release and re-uptake. It also noncompetitively antagonises N-methyl-D-aspartate. As an antiviral drug, it inhibits replication of influenza type A virus. Absorption: Readily absorbed from the GIT (oral); peak concentrations after 4 hrs. Distribution: Crosses the placenta and the blood-brain barrier; enters breast milk. Protein binding: 67%. Excretion: Mainly via urine by glomerular filtration and tubular secretion (as unchanged and small amounts of an acetylated metabolite); 11-15 hrs (elimination half-life), significantly prolonged in the elderly and renal impairment; may be increased by acidification of the urine. |
||||||||||||||||||||||||
Administration |
Should be taken with food. |
||||||||||||||||||||||||
Storage Conditions |
Oral: Store at 20-25°C. | ||||||||||||||||||||||||
ATC Classification |
N04BB01 - amantadine ; Belongs to the class of adamantine derivative dopaminergic agents. Used in the management of Parkinson's disease. | ||||||||||||||||||||||||
Storage |
Oral: Store at 20-25°C. | ||||||||||||||||||||||||
Available As |
|
Amantadine
Post Review about Amantadine Click here to cancel reply.
Amantadine Containing Brands
Amantadine is used in following diseases
Drug - Drug Interactions of Amantadine
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.